Transplant characteristics
| . | Donor source . | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| . | MRD (N = 3511) . | MUD 10/10 (N = 1959) . | MUD 9/10 (N = 549) . | UCB (N = 333) . | Haplo (N = 193) . | |||||
| Conditioning | P < .001 | |||||||||
| MAC | 1951 | 56% | 888 | 45% | 256 | 47% | 145 | 44% | 104 | 54% |
| RIC | 1518 | 43% | 1056 | 54% | 291 | 53% | 183 | 55% | 89 | 46% |
| Missing | 42 | 1% | 15 | 1% | 2 | 0% | 5 | 2% | 0 | |
| Peripheral stem cells | P < .001 | |||||||||
| No | 712 | 20% | 315 | 16% | 76 | 14% | 333 | 100% | 100 | 52% |
| Yes | 2799 | 80% | 1644 | 84% | 473 | 86% | 0 | 93 | 48% | |
| CMV patient/donor | P < .001 | |||||||||
| neg/neg | 717 | 20% | 585 | 30% | 129 | 23% | 64 | 19% | 32 | 17% |
| pos/neg | 522 | 15% | 582 | 30% | 166 | 30% | 93 | 28% | 35 | 18% |
| neg/pos | 324 | 9% | 166 | 8% | 74 | 13% | 42 | 13% | 12 | 6% |
| pos/pos | 1587 | 45% | 582 | 30% | 166 | 30% | 78 | 23% | 111 | 58% |
| Missing | 361 | 10% | 44 | 2% | 14 | 3% | 56 | 17% | 3 | 2% |
| TBI given | P < .001 | |||||||||
| No | 2480 | 71% | 1422 | 73% | 424 | 77% | 130 | 39% | 141 | 73% |
| Yes | 1028 | 29% | 535 | 27% | 124 | 23% | 203 | 69% | 52 | 27% |
| Female donor to male recipient | P < .001 | |||||||||
| No | 2710 | 77% | 1739 | 89% | 472 | 86% | 273 | 82% | 147 | 76% |
| Yes | 801 | 23% | 220 | 11% | 77 | 14% | 60 | 18% | 46 | 24% |
| In vivo T-cell depletion | P < .001 | |||||||||
| No | 2354 | 67% | 535 | 27% | 73 | 13% | 198 | 59% | 111 | 58% |
| ATG | 707 | 20% | 1201 | 61% | 393 | 72% | 123 | 37% | 78 | 40% |
| Alemtuzumab | 237 | 7% | 216 | 11% | 80 | 15% | 0 | 3 | 2% | |
| Missing | 213 | 6% | 7 | 0% | 3 | 1% | 12 | 4% | 1 | 1% |
| . | Donor source . | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| . | MRD (N = 3511) . | MUD 10/10 (N = 1959) . | MUD 9/10 (N = 549) . | UCB (N = 333) . | Haplo (N = 193) . | |||||
| Conditioning | P < .001 | |||||||||
| MAC | 1951 | 56% | 888 | 45% | 256 | 47% | 145 | 44% | 104 | 54% |
| RIC | 1518 | 43% | 1056 | 54% | 291 | 53% | 183 | 55% | 89 | 46% |
| Missing | 42 | 1% | 15 | 1% | 2 | 0% | 5 | 2% | 0 | |
| Peripheral stem cells | P < .001 | |||||||||
| No | 712 | 20% | 315 | 16% | 76 | 14% | 333 | 100% | 100 | 52% |
| Yes | 2799 | 80% | 1644 | 84% | 473 | 86% | 0 | 93 | 48% | |
| CMV patient/donor | P < .001 | |||||||||
| neg/neg | 717 | 20% | 585 | 30% | 129 | 23% | 64 | 19% | 32 | 17% |
| pos/neg | 522 | 15% | 582 | 30% | 166 | 30% | 93 | 28% | 35 | 18% |
| neg/pos | 324 | 9% | 166 | 8% | 74 | 13% | 42 | 13% | 12 | 6% |
| pos/pos | 1587 | 45% | 582 | 30% | 166 | 30% | 78 | 23% | 111 | 58% |
| Missing | 361 | 10% | 44 | 2% | 14 | 3% | 56 | 17% | 3 | 2% |
| TBI given | P < .001 | |||||||||
| No | 2480 | 71% | 1422 | 73% | 424 | 77% | 130 | 39% | 141 | 73% |
| Yes | 1028 | 29% | 535 | 27% | 124 | 23% | 203 | 69% | 52 | 27% |
| Female donor to male recipient | P < .001 | |||||||||
| No | 2710 | 77% | 1739 | 89% | 472 | 86% | 273 | 82% | 147 | 76% |
| Yes | 801 | 23% | 220 | 11% | 77 | 14% | 60 | 18% | 46 | 24% |
| In vivo T-cell depletion | P < .001 | |||||||||
| No | 2354 | 67% | 535 | 27% | 73 | 13% | 198 | 59% | 111 | 58% |
| ATG | 707 | 20% | 1201 | 61% | 393 | 72% | 123 | 37% | 78 | 40% |
| Alemtuzumab | 237 | 7% | 216 | 11% | 80 | 15% | 0 | 3 | 2% | |
| Missing | 213 | 6% | 7 | 0% | 3 | 1% | 12 | 4% | 1 | 1% |
TBI, total body irradiation.